Clinical trials: Retinopathy of Prematurity Both Eyes
Retinopathy of Prematurity Both Eyes, Retinal Disease
VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP
The Retinopathy of Prematurity (ROP) is one of the leading causes of blindness on the pediatric age worldwide. This pathology is characterized for arrest of the normal vascular and neuronal retina that because of pathological…
- Conditions
- Retinopathy of Prematurity Both Eyes, Retinal Disease, Premature Birth, Eye Diseases
- Trial name
- NCT03148132
- Testing
- Bevacizumab Injection, Ranibizumab Ophthalmic
- Where
- Mexico
- Volunteers
- 16 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
Retinopathy of Prematurity Both Eyes, Retinal Disease
Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries
This study aims to study the safety and efficacy of using an 18 mm short vitrectomy probe for pediatric vitreoretinal surgeries and to investigate the surgeon's comfort and reliability of using the shorter probe.
- Conditions
- Retinopathy of Prematurity Both Eyes, Retinal Disease, Persistent Fetal Vasculature, Coats Disease
- Trial name
- NCT06520410
- Testing
- Pars plana vitrectomy with a 18 mm short vitrector
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Retinopathy of Prematurity Both Eyes
Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity
Retinopathy of prematurity (ROP) with inadequate growth and development of retinal blood vessels in premature infants is one of the foremost reasons for childhood blindness.
- Trial name
- NCT05033106
- Testing
- Bevacizumab, Ranibizumab
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Zagazig University